表 2.
乙型肝炎病毒感染自然病程不同分期患者的临床特征
Information and clinical characteristics of patients at different stages of chronic hepatitis B virus infection disease progression
| Stages | HBeAg positive | HBeAg negative | P value | |||
| Chronic HBV carrier statusa(n=173) | Chronic hepatitisb(n=329) | Inactive HBsAg carrier statusc(n=95) | Chronic hepatitisd(n=163) | |||
| a, immune tolerant phase; b, immune clearance phase; c, immune control phase; d, reactivation phase; e, quantitative variables that do not follow a normal distribution are expressed as M (P25, P75), and comparisons between groups are conducted using the Kruskal-Wallis test, and Kruskal-Wallis one-way ANOVA test post-hoc test; f, variables are expressed as number (%); g, quantitative variables that complied with normality are expressed as mean ± standard deviation, and comparisons are performed using the ANOVA, and Tukeys post-hoc test. * P < 0.05, compared with HBeAg positive patients with non/minimal liver injury; # P < 0.05, compared with HBeAg positive patients with evident liver injury; △ P < 0.05, compared with HBeAg negative patients with non/minimal liver injury; ▲ P < 0.05, compared with HBeAg negative patients with evident liver injury. HBeAg, hepatitis B e antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphates; GGT, gamma glutamyl transferase; ALB, albumin; PA, prealbumin; PT, prothrombin time; PLT, platelet. | ||||||
| Age/yearse | 25 (11, 34)△▲ | 24 (12, 33)△▲ | 39 (32, 47)*# | 37 (29, 46)*# | < 0.001 | |
| Gender, n(%)f | ||||||
| Male, | 106 (61.3) | 201 (61.1) | 53 (55.8) | 96 (58.9) | 0.785 | |
| Female | 67 (38.7) | 128 (38.9) | 42 (44.2) | 67 (41.1) | ||
| Serum indicators of virological | ||||||
| HBV DNA/(lg IU/mL)e | 8.00 (7.56, 8.54)#△▲ | 7.77 (6.89, 8.24)*△▲ | 3.12 (2.40, 4.00)*# | 3.97 (2.72, 5.32)*# | < 0.001 | |
| HBsAg/(lg IU/mL)e | 4.61 (4.06, 4.85)#△▲ | 4.09 (3.66, 4.52)*△▲ | 3.21 (2.60, 3.60)*# | 3.39 (2.95, 3.72)*# | < 0.001 | |
| Serum biochemical indicators | ||||||
| ALT/(U/L)e | 41 (25, 65)#△ | 112 (50, 263)*△▲ | 22 (16, 38)*▲ | 31 (20, 71)#△ | < 0.001 | |
| AST/(U/L)e | 32 (24, 49)#△ | 77 (40, 149)*△▲ | 23 (19, 30)* #▲ | 30 (21, 52)#△ | < 0.001 | |
| ALP/(U/L)e | 89 (66, 211)#△▲ | 108 (78, 235)*△▲ | 75 (61, 91)* # | 79 (64, 103)*# | < 0.001 | |
| GGT/(U/L)e | 15 (12, 20)#▲ | 29 (16, 51)*△▲ | 17 (13, 24)#▲ | 21 (15, 38)*#△ | < 0.001 | |
| Serum indicators of liver function | ||||||
| ALB/(g/L)e | 41 (38, 44) | 40 (38, 43)△▲ | 43 (40, 45)# | 42 (39, 44)# | < 0.001 | |
| PA/(mg/L)g | 195±46#△ | 151±46*△▲ | 215±48*#▲ | 187±52#△ | ||
| PT/se | 11.1 (10.6, 11.7)# | 11.4 (10.8, 11.9)*△ | 10.8 (10.3, 11.4)#▲ | 11.3 (10.7, 11.9)△ | < 0.001 | |
| PLT/(×109/L)e | 218 (190, 260)△▲ | 206 (172, 252)▲ | 196 (164, 234)* | 180 (145, 220)*# | ||
| Histological assessment | ||||||
| Inflammation grade, n (%)f | ||||||
| G0-G1 | 173 (100.0) | 55 (16.7) | 95 (100.0) | 87 (53.4) | ||
| G2-G4 | 0 (0.0) | 274 (83.3) | 0 (0.0) | 76 (46.6) | ||
| Fibrosis Stage, n (%)f | ||||||
| S0-1 | 173 (100.0) | 87 (26.4) | 95 (100.0) | 12 (7.4) | ||
| S2-4 | 0 (0.0) | 242 (73.6) | 0 (0.0) | 151 (92.6) | ||